# 1 **Plasma Markers of Disrupted Gut Permeability in Severe COVID-19**  2 **Patients**

- 3 **Authors**: Leila B. Giron<sup>1</sup>, Harsh Dweep<sup>1</sup>, Xiangfan Yin<sup>1</sup>, Han Wang<sup>1</sup>, Mohammad Damra<sup>1</sup>, Aaron R.
- 4 Goldman<sup>1</sup>, Nicole Gorman<sup>1</sup>, Clovis S. Palmer<sup>2,3</sup>, Hsin-Yao Tang<sup>1</sup>, Maliha W. Shaikh<sup>4</sup>, Christopher B.
- 5 Forsyth<sup>4</sup>, Robert A. Balk,<sup>4</sup> Netanel F Zilberstein,<sup>4</sup> Qin Liu<sup>1</sup>, Andrew Kossenkov<sup>1</sup>, Ali Keshavarzian<sup>4</sup>,
- 6 Alan Landay<sup>4</sup>, Mohamed Abdel-Mohsen<sup>1\*</sup>

7

- 8 **Affiliations**: <sup>1</sup>The Wistar Institute, Philadelphia, PA, 19104, USA; <sup>2</sup>The Burnet Institute, Melbourne,
- 9 Victoria, 3004, Australia; <sup>3</sup> Department of Infectious Diseases, Monash University, Melbourne, Victoria,
- 10 3004, Australia; <sup>4</sup>Rush University, Chicago, IL, 60612, USA.

11

\* 12 **Corresponding author and address:** Mohamed Abdel-Mohsen, Ph.D. Assistant Professor, The 13 Wistar Institute, Philadelphia, PA, USA, 19104, E-mail: mmohsen@wistar.org

14

15 **Key Words:** SARS-CoV2; COVID-19; Microbial Translocation; Inflammation; Zonulin.

#### 16 **ABSTRACT**

17 A disruption of the crosstalk between the gut and the lung has been implicated as a driver of 18 severity during respiratory-related diseases. Lung injury causes systemic inflammation, which 19 disrupts gut barrier integrity, increasing the permeability to gut microbes and their products. This 20 exacerbates inflammation, resulting in positive feedback. We aimed to test whether severe 21 Coronavirus disease 2019 (COVID-19) is associated with markers of disrupted gut permeability. 22 We applied a multi-omic systems biology approach to analyze plasma samples from COVID-19 23 patients with varying disease severity and SARS-CoV-2 negative controls. We investigated the 24 potential links between plasma markers of gut barrier integrity, microbial translocation, systemic 25 inflammation, metabolome, lipidome, and glycome, and COVID-19 severity. We found that 26 severe COVID-19 is associated with high levels of markers of tight junction permeability and 27 translocation of bacterial and fungal products into the blood. These markers of disrupted 28 intestinal barrier integrity and microbial translocation correlate strongly with higher levels of 29 markers of systemic inflammation and immune activation, lower levels of markers of intestinal 30 function, disrupted plasma metabolome and glycome, and higher mortality rate. Our study 31 highlights an underappreciated factor with significant clinical implications, disruption in gut 32 functions, as a potential force that may contribute to COVID-19 severity.

#### 33 **INTRODUCTION**

34 Coronavirus Disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome 35 coronavirus 2 (SARS-CoV-2) infection, can manifest with diverse clinical presentations. While the 36 majority of infected individuals exhibit asymptomatic or mild respiratory tract infection, a significant 37 population face severe manifestations such as acute respiratory distress syndrome (ARDS), multi-organ 38 failure, and death (1). A state of hyper-inflammation and hyperactivated immune responses, 39 characterized by an ensuing cytokine storm and increased complement activation, has been associated 40 with COVID-19 severity (1, 2). However, the pathophysiological mechanisms that contribute to these 41 phenomena remain mostly unknown. Understanding these mechanisms is a crucial step in designing 42 rational clinical and therapeutic strategies.

43 A disruption of the crosstalk between the gut and the lung has been implicated as a driver of severity 44 during respiratory-related diseases, including ARDS (3, 4). Systemic inflammation caused by a lung 45 infection or injury can lead to a disruption of the gut barrier integrity and increase the permeability to 46 gut microbes and microbial products. This microbial translocation can exacerbate systemic inflammation 47 and lung injury – resulting in positive feedback (3, 4). In addition, SARS-CoV-2 can directly infect gut 48 cells (5), and viral infections of the gut cause changes in gut structure and breakdown of the epithelial 49 barrier (6).

50 Even as microbial translocation impacts systemic inflammation directly, it may also impact it indirectly 51 by modulating circulating levels of gut- and gut microbiota-associated products such as metabolites and 52 lipids. Plasma metabolites and lipids can reflect the functional status of the gut and the metabolic 53 activity of its microbiota (7). They also are biologically active molecules in their own right, regulating 54 several immunological functions, including inflammatory responses (8). A third class of microbial 55 products that can translocate from the gut is glycan-degrading enzymes. Glycans on circulating 56 glycoproteins and antibodies (IgGs and IgAs) are essential for regulating several immunological 57 responses, including complement activation (9). The glycan-degrading enzymes are released by several 58 members of the gut microbiome and their translocation can alter the circulating glycome, leading to 59 higher inflammation and complement activation (10). Indeed, altered glycosylation of plasma 60 glycoproteins (including immunoglobulin G, IgG) has been associated with the onset and progression of 61 inflammatory bowel disease (IBD) (11). Furthermore, modulation of the gut microbiota via fecal 62 microbiota transplantation affects IgG and serum glycosylation (12).

63 Here, we aimed to examine whether severe COVID-19 is associated with plasma markers of disrupted 64 gut functions. Towards this aim, we applied a multi-omic systems biology approach to analyze plasma 65 samples from COVID-19 patients with varying disease severity and SARS-CoV-2 negative controls.

66

#### 67 **MATERIALS AND METHODS**

68 *Study main cohort.* Main analyses were performed using plasma samples from 60 individuals tested 69 positive for SARS-CoV-2 and 20 SARS-CoV-2 negative controls collected at Rush University Medical 70 Center (RUMC). The 60 SARS-CoV-2 positives were selected to represent three disease states: 20 with 71 mild symptoms (outpatients); 20 with moderate symptoms (inpatients hospitalized on regular wards); 72 and 20 with severe symptoms (inpatients hospitalized in an intensive care unit (ICU)) (**Figure 1a**). 73 Individuals were selected to have a median age between 52.5 to 58.5 years. There was no significant 74 difference in age between groups (**Supplementary Figure 1**). The study cohort was also chosen to have 75 a 35 to 60% representation of female gender per disease status group (**Supplementary Table 1**). Eight

76 participants of the cohort (two from the moderate group and six from the severe group) died from 77 COVID-19 (**Supplementary Table 1**).

78 *Study validation cohort.* Key measurements (zonulin, LBP, and soluble CD14) were confirmed using 79 plasma samples from an independent cohort of 57 individuals tested positive for SARS-CoV-2 and 18 80 SARS-CoV-2 negative controls collected at RUMC. The 57 SARS-CoV-2 positives were selected to 81 represent three disease states: 20 with mild symptoms (outpatients); 18 with moderate symptoms 82 (inpatients hospitalized on regular wards); and 19 with severe symptoms (inpatients hospitalized in an 83 ICU) (**Supplementary Table 2**).

84 *Ethics.* All research protocols of the study were approved by the institutional review board (IRB) at 85 Rush University (20070905-IRB01; approved July-27-2020) and at the Wistar Institute. All human 86 experimentation was conducted in accordance with the guidelines of the US Department of Health and 87 Human Services and those of the authors' institutions.

88 *Measurement of plasma markers of tight junction permeability and microbial translocation.* Plasma 89 levels of soluble CD14 (sCD14), soluble CD163 (sCD163), LPS Binding Protein (LBP), and FABP2/I-90 FABP were quantified using DuoSet ELISA kits (R&D Systems; catalog # DY383-05, # DY1607-05, # 91 DY870-05, and # DY3078, respectively). The plasma level of zonulin was measured using an ELISA kit 92 from MyBiosorce (catalog # MBS706368). Levels of occludin were measured by ELISA (Biomatik; 93 catalog # EKC34871). β-glucan detection in plasma was performed using Limulus Amebocyte Lysate<br>94 (LAL) assay (Glucatell Kit, CapeCod; catalog # GT003). Plasma levels of Reg3A were measured by 94 (LAL) assay (Glucatell Kit, CapeCod; catalog # GT003). Plasma levels of Reg3A were measured by

95 ELISA (RayBiotech; catalog # ELH-REG3A-1).

96 Measurement of plasma markers of inflammation and immune activation. Plasma levels of GM-CSF, 97 IFN-β, IFN-γ, IL-10, IL-13, IL-1β, IL-33, IL-4, IL-6, TNF-α, Fractalkine, IL-12p70, IL-2, IL-21, IL-22, 98 IL-23, IP-10, MCP-2, MIP-1α, SDF-1a, IFN-α2a, IL-12/IL-23p40, and IL-15 were determined using 98 IL-23, IP-10, MCP-2, MIP-1 $\alpha$ , SDF-1a, IFN- $\alpha$ 2a, IL-12/IL-23p40, and IL-15 were determined using customized MSD U $\Box$ PLEX multiplex assay (Meso Scale Diagnostic catalog# K15067L-2). Plasma 99 customized MSD U**PLEX** multiplex assay (Meso Scale Diagnostic catalog# K15067L-2). Plasma<br>100 levels of C-Reactive Protein (CRP), Galectin-1, Galectin-3, and Galectin-9 were measured using DuoSet levels of C-Reactive Protein (CRP), Galectin-1, Galectin-3, and Galectin-9 were measured using DuoSet 101 ELISA kits (R&D Systems; catalog # DY1707, # DY1152-05, # DY2045, and # DY1154, respectively). 102 Levels of Growth Differentiation Factor-15 (GDF-15) were measured by ELISA using GDF-15 103 Quantikine ELISA Kit (R&D Systems; catalog # DGD150). Plasma levels of Myeloperoxidase (MPO), 104 d-dimer, and C3a were measured by ELISA (Thermo Fischer; catalog # BMS2038INST, # 105 EHDDIMER, #BMS2089, respectively).

106 *Untargeted measurement of plasma metabolites and lipids.* Metabolomics analysis was performed as 107 described previously (13). Lipidomics analysis was performed as described previously (14).

108 *IgG isolation.* Bulk IgG was purified from plasma using Pierce Protein G Spin Plate (Thermo Fisher; 109 catalog # 45204). IgG purity was confirmed by SDS gel.

110 *IgA isolation.* Bulk IgA was purified from IgG depleted plasma using CaptureSelect IgA Affinity 111 Matrix (Thermo Fisher; catalog # 194288010). IgA was concentrated using Amicon® filters (Milipore 112 catalog #UFC805024), and purity was confirmed by SDS gel.

113 *N-glycan analysis using capillary electrophoresis.* For both plasma and bulk IgG, *N*-glycans were 114 released using peptide-N-glycosidase F (PNGase F) and labeled with 8-aminopyrene-1,3,6-trisulfonic 115 acid (APTS) using the GlycanAssure APTS Kit (Thermo Fisher; catalog # A33952), following the 116 manufacturer's protocol. Labeled *N*-glycans were analyzed using the 3500 Genetic Analyzer capillary 117 electrophoresis system. Total plasma *N*-glycans were separated into 24 peaks (**Supplementary Table 3**)

118 and IgG *N*-glycans into 22 peaks (**Supplementary Table 4**)**.** The relative abundance of *N*-glycan 119 structures was quantified by calculating the area under the curve of each glycan structure divided by the 120 total glycans using the Applied Biosystems GlycanAssure Data Analysis Software Version 2.0.

121 *Glycan analysis using lectin array.* To profile plasma total and IgA glycomes, we used the lectin 122 microarray as it enables analysis of multiple glycan structures. The lectin microarray employs a panel of 123 45 immobilized lectins with known glycan-binding specificity (lectins and their glycan-binding 124 specificity are detailed in **Supplementary Table 5**). Plasma proteins or isolated IgA were labeled with 125 Cy3 and hybridized to the lectin microarray. The resulting chips were scanned for fluorescence intensity 126 on each lectin-coated spot using an evanescent-field fluorescence scanner GlycoStation Reader 127 (GlycoTechnica Ltd.), and data were normalized using the global normalization method.

128 *Statistical analysis.* Kruskal-Wallis and Mann–Whitney U tests were used for unpaired comparisons. 129 Spearman's rank correlations were used for bivariate correlation analyses. Severity correlation 130 coefficient (SC *rho*) tested correlation versus patient groups with the severity groups quantified as 131 follows: control=1, mild=2, moderate=3, severe=4. FDR for each type of comparison was calculated 132 using the Benjamini–Hochberg approach within each data subset separately, and FDR<0.05 was used as 133 a significance threshold. Principal Component Analysis was performed on log2-transformed z-scored 134 data. Pathway enrichment analyses were done on features that passed significant SC *rho* at FDR<0.05. 135 Enrichments for the metabolites were tested using QIAGEN's Ingenuity® Pathway Analysis software 136 (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) using the "Canonical Pathway" option. 137 Enrichments for the lipids were done using LIPEA (https://lipea.biotec.tu-dresden.de/home) with default 138 parameters. To explore biomarkers that could distinguish clinical outcome (hospitalization vs. non-139 hospitalization), a specific set of microbial translocation variables were identified among those with 140 FDR<0.05. Variables for the multivariable logistic model were selected from the identified specific set 141 of biomarkers using the Lasso technique with the cross-validation (CV) selection option by separating 142 data in 5-fold. Due to the exploratory nature of this study with a moderate sample size, variable selection 143 was determined using 100 independent rounds runs of CV Lasso with minimum tuning 144 parameter lambda. The markers that were selected 80 or more times from 100 runs were used as a final 145 set of variables in our model. The ability of the final logistic model was assessed by AUC with a 95% 146 confidence interval. Statistical analyses were performed in R 4.0.2 and Prism 7.0 (GraphPad).

147

#### 148 **RESULTS**

149 *Characteristics of the study main cohort and study overview***.** We collected plasma samples from 60 150 individuals testing positive for SARS-CoV-2 (by RT-PCR) and 20 SARS-CoV-2 negative controls. The 151 60 SARS-CoV-2 positive individuals were selected to represent three disease states: 20 with mild 152 symptoms (outpatients); 20 with moderate symptoms (inpatients hospitalized on regular wards); and 20 153 with severe symptoms (inpatients hospitalized in an intensive care unit (ICU)) (**Figure 1a**). Individuals 154 were selected to have a median age between 52.5 to 58.5 years. There was no significant difference in 155 age between groups (**Supplementary Figure 1**). The study cohort was also chosen to have a 35 to 60% 156 representation of female gender per disease status group (**Supplementary Table 1**). Samples from 157 hospitalized patients (moderate and severe groups) were collected at the time of diagnosis when the 158 patient was admitted (**Supplementary Table 1**). Eight individuals of the cohort (two from the moderate 159 group and six from the severe group) died from COVID-19 (**Supplementary Table 1**). The plasma 160 samples from all individuals in this cohort were used in a multi-omic, systems biology approach that 161 measured: markers of tight junction permeability and microbial translocation using ELISA and Limulus 162 Amebocyte Lysate assays; inflammation and immune activation/dysfunction markers using ELISA and

163 multiplex cytokine arrays; untargeted metabolomic and lipidomic analyses using mass spectrometry

164 (MS); and plasma glycomes (from total plasma glycoproteins, isolated immunoglobulin G (IgG), and

165 isolated immunoglobulin A (IgA)) using capillary electrophoresis and lectin microarray (**Figure 1a** and

166 **Supplementary Table 6**).

167 *Severe COVID-19 is associated with high levels of markers of tight junction permeability and*  168 *microbial translocation***.** We first asked whether severe COVID-19 is associated with differences in 169 plasma markers of tight junction permeability and microbial translocation. We measured the plasma 170 levels of eight established drivers and markers of intestinal barrier integrity (**Supplementary Table 6**). 171 We found that severe COVID-19 is associated with high levels of zonulin (**Figure 1b**). Zonulin 172 (haptoglobin 2 precursor) is an established mediator of tight junction permeability in the digestive tract, 173 where higher levels of zonulin drive increases in tight junction permeability (15, 16). Notably, 174 hospitalized individuals with higher plasma levels of zonulin were more likely to die compared to 175 hospitalized individuals with lower levels of zonulin (**Figure 1c**).

176 These higher levels of zonulin could enable the translocation of microbes and their products from the gut 177 into the blood, including parts of the cell wall of bacteria and fungus (17, 18). To test this supposition, 178 we measured plasma levels of common bacterial and fungal markers. Exposure to bacterial endotoxin 179 can be determined by measuring plasma lipopolysaccharide (LPS) binding protein (LBP). LBP is an 180 acute-phase protein that binds to LPS to induce immune responses (19). Indeed, we observed high levels 181 of LBP in individuals with severe COVID-19 compared to individuals with mild COVID-19 or controls 182 (**Figure 1d**). We also found higher levels of β-glucan, a polysaccharide cell wall component of most fungal species and a marker of fungal translocation (20), in individuals with severe COVID-19 fungal species and a marker of fungal translocation (20), in individuals with severe COVID-19 184 compared to those with mild COVID-19 or controls (**Figure 1e**). In addition, there were significantly 185 higher levels (FDR=0.025) of the tight junction protein occludin in the severe group compared to 186 controls (data not shown). There also was a strong trend (FDR  $= 0.051$ ) toward higher levels of the 187 protein 3-alpha ( $REG3\alpha$ ), a marker of intestinal stress, comparing the severe and mild groups (data not 188 shown). We did not observe high levels of intestinal fatty-acid binding protein (I-FABP), a marker of shown). We did not observe high levels of intestinal fatty-acid binding protein (I-FABP), a marker of 189 enterocyte apoptosis, suggesting that the high levels of tight junction permeability and microbial 190 translocation are not associated with enterocyte death.

191 These high levels of tight junction permeability and microbial (both bacterial and fungal) translocation 192 are expected to lead to microbial-mediated myeloid inflammation. Indeed, levels of soluble CD14 193 (sCD14; monocyte inflammation marker) (**Figure 1f**) and myeloperoxidase (MPO; neutrophil 194 inflammation marker) (**Figure 1g**) were significantly higher during severe COVID-19 compared to mild 195 and control groups. Levels of soluble CD163 (sCD163) were also higher significantly (FDR=0.04) in 196 the severe group compared to controls (data not shown). These data suggest that COVID-19 severity and 197 mortality are associated with plasma markers of higher tight junction permeability and higher 198 translocation of bacterial and fungal products to the blood.

199 *Microbial translocation is linked to systemic inflammation.* Higher levels of microbial translocation 200 should lead to higher systemic inflammation. We measured the levels of 31 markers of systemic 201 inflammation (**Supplementary Table 6**), including: 23 cytokines and chemokines (such as IL-6, IL-1β, 202 MCP-1, IP-10, and TNF $\alpha$ ), markers of inflammation and thrombogenesis (such as C-reactive protein (CRP) and D-dimer), a marker of complement activation (C3a), a marker of oxidative stress (GDF-15),  $(CRP)$  and D-dimer), a marker of complement activation  $(C3a)$ , a marker of oxidative stress (GDF-15), 204 and three immunomodulatory galectins (galectin-1, -3, and -9). As anticipated, the levels of many of 205 these markers were higher in patients with severe COVID-19 compared to patients with mild COVID-19 206 or controls (**Figure 2a-left**). In particular, we observed higher levels of several cytokines and 207 inflammatory markers. In addition to the expected changes, we also observed significantly higher levels 208 of the immunomodulatory lectins, galectin-3 (**Figure 2b**) and galectin-9 (**Figure 2c**). Levels of Gal-9

209 were higher in the plasma of hospitalized patients who eventually died compared to survivors (**Figure**  210 **2d**). Last, notable dysregulations were observed in levels of C3a (**Figure 2e**; indicative of complement 211 activation) and GDF-15 (**Figure 2f**; indicative of oxidative stress), with the levels of GDF-15 higher in

212 deceased hospitalized patients compared to survivors (**Figure 2g**).

213 Next, we examined the correlations between the markers of intestinal barrier integrity (zonulin) or 214 microbial translocation (LBP and  $\beta$ -glucan) and the 31 markers of systemic inflammation and immune activation. As shown in **Figure 2a-right**, higher levels of zonulin, LBP, or  $\beta$ -glucan were strongly 215 activation. As shown in **Figure 2a-right**, higher levels of zonulin, LBP, or β-glucan were strongly positively correlated with higher levels of many of the markers of systemic inflammation and immune 217 activation, including IL-6 (**Figure 2h-i**). These data suggest that the potential disruption of the gut 218 barrier integrity and microbial translocation during severe COVID-19 is associated with systemic 219 inflammation. Our results do not imply that microbial translocation is the primary trigger of this 220 inflammation, as it is likely that many pathophysiological pathways are involved in inflammation during 221 COVID-19. However, the robust literature indicating that microbial translocation can fuel inflammation 222 is consistent with our findings.

223 *Severe COVID-19 is associated with a plasma metabolomic profile that may reflect disrupted gut*  224 *function.* A second set of factors that may reflect the functional state of the gut and its microbiota are 225 the plasma metabolites. Importantly, many of these are biologically active molecules that can directly 226 impact immunological and inflammatory responses. We performed untargeted metabolomic analysis 227 (using LC-MS/MS). Within the 80 plasma samples, we identified a total of polar 278 metabolites. We 228 observed a significant metabolomic shift during severe COVID-19 (**Figure 3a**, a list of the top 50 229 dysregulated metabolites is in **Supplementary Figure 2**). Indeed, in principal component analysis of the 230 full metabolomic dataset, the first component was able to completely distinguish controls (and mild 231 patients) from those with severe disease. Pathway analysis of the COVID-19-dysregulated metabolites 232 showed disruption in tRNA charging, citrulline metabolism, and several other amino acid (AA) 233 metabolic pathways (**Figure 3b,** the top 10 dysregulated metabolic pathways are shown; 234 **Supplementary Table 7** shows the top 50 dysregulated metabolic pathways with FDR<0.05). 235 Importantly, changes in AA metabolism, including citrulline, arginine, methionine, and tryptophan (see **236 Figure 3b**) can influence the AA $\Box$ metabolizing bacterial communities and disrupt the gut $\Box$ microbiome immune axis (21). AA are absorbed and metabolized by enterocytes and gut microbiota. Consumption of immune axis (21). AA are absorbed and metabolized by enterocytes and gut microbiota. Consumption of 238 AA by the gut microbiome is important for bacterial growth and is involved in the production of key 239 microbiome-related metabolites (21).

240 Next, we focused on 50 of the metabolites (out of the total of 278) that are known to be associated with 241 the function of the gut and its microbiota (**Supplementary Table 8** lists the 50 metabolites and their 242 references). Levels of most of these gut-associated plasma metabolites (35 out of 50) were dysregulated 243 during severe COVID-19 compared to mild disease or controls (**Table 1** and **Figure 3c**). Within this 244 metabolic signature of COVID-19-associated gut dysfunction is citrulline, which is also identified as a 245 top metabolic pathway dysregulated by severe COVID-19 (**Figure 3b**). Citrulline is an amino acid 246 produced only by enterocytes and an established marker of gut and enterocyte function (22). Its levels 247 are significantly lower during severe COVID-19 (**Figure 3d)**. Also, within this metabolic signature is 248 succinic acid, a marker of gut microbial dysbiosis, whose levels are higher during severe COVID-19 249 (**Figure 3e**).

250 Notable differences were also observed in several metabolites involved in the catabolism of the AA 251 tryptophan (**Figure 3b, c**). Higher levels of tryptophan catabolism, indicated by high levels of 252 kynurenine and low levels of tryptophan (i.e., the [Kyn/Trp] ratio), is a marker of gut microbial 253 dysbiosis (23). Indeed, we observed a higher [Kyn/Trp] ratio in individuals with severe COVID-19 than 254 in those with mild disease or controls (**Figure 3f**). Furthermore, lower levels of tryptophan and higher

255 levels of kynurenic acid were associated with mortality among hospitalized COVID-19 patients (**Figure**  256 **3g-h**). Together, these data indicate that a metabolic signature associated with severe COVID-19 is 257 compatible with disrupted gut functions and dysregulated gut $\Box$ microbiome axis. However, it is  $258$  important to note that many of these metabolic pathways are multi-faceted and can also reflect 258 important to note that many of these metabolic pathways are multi-faceted and can also reflect 259 dysregulations in multiple-organ systems.

260 *Plasma metabolomic markers of COVID-19-associated gut dysfunction associate with higher*  261 *inflammation and immune dysfunction.* As noted above, many plasma metabolites are bioactive 262 molecules that can directly impact immunological and inflammatory responses. Therefore, we sought to 263 identify links between the 35 dysregulated gut-associated plasma metabolites (**Table 1**) and the 264 dysregulated markers of microbial translocation, inflammation, and immune activation (**Figure 2a**). We 265 observed strong links between levels of the dysregulated gut-associated metabolites and levels of 266 markers of microbial translocation (**Figure 4a**) as well as levels of inflammation and immune activation 267 (**Figure 4b**). Notable correlations were observed between lower levels of citrulline and higher IL-6 268 (**Figure 4c**), higher levels of succinic acid and higher IL-6 (**Figure 4d**), and higher [Kyn/Trp] ratio and 269 higher IL-6 (**Figure 4e**). These data highlight the potential links between disrupted metabolic activities, 270 especially those related to the gut and its microbiota, and systemic inflammation and immune 271 dysfunction during COVID-19.

272 *Severe COVID-19 is associated with disrupted lipid metabolism.* Intermediary metabolites and sulfur-273 containing amino acids are potent modulators of lipid metabolism. Therefore, we performed lipidomic 274 analysis and identified a total of 2015 lipids using untargeted MS. Similar to the plasma metabolome, 275 the plasma lipidome shifted significantly during severe COVID-19 (**Figure 5a)**. These 2015 lipids were 276 divided into 24 lipids classes (**Supplementary Table 9**); out of these 24 classes, 16 were significantly 277 (FDR<0.05) different in the moderate and severe COVID-19 groups (11 were lower whereas five were 278 higher compared to the mild or control groups) (**Figure 5b**). Pathway analysis of this severe-COVID-279 19-associated lipidomic signature showed that glycerophospholipid and choline metabolism were the 280 most significantly dysregulated pathways (**Figure 5c**). The gut microbiota is heavily involved in these 281 two interconnected pathways (24). Gut microbial dysbiosis can alter the digestion and absorption of 282 glycerophospholipids, leading to several diseases (25, 26).

283 It is also known that COVID-19 severity is linked to pre-existing cardiometabolic-associated diseases 284 (27). Furthermore, COVID-19 itself can cause liver dysfunction (28). Indeed, many of the individuals in 285 our main cohort with moderate and severe COVID-19 had diabetes and/or high blood pressure. We 286 sought to examine whether these conditions contribute to our main findings. We examined the 287 differences in the levels of zonulin, LBP,  $\beta$ -glucan, sCD14, and IL-6 between hospitalized patients 288 (moderate and severe groups) who had diabetes or not (**supplementary Figure 3a**), or patients who had 288 (moderate and severe groups) who had diabetes or not (**supplementary Figure 3a**), or patients who had 289 high blood pressure or not (**supplementary Figure 3b**). We did not observe any significant difference in 290 the levels of these selected markers between these groups. However, the contribution of pre-existing 291 metabolic conditions and post-infection intestinal and liver complications to the observed disrupted 292 plasma profiles warrant further investigation.

293

294 *Severe COVID-19 is associated with altered plasma glycomes that are linked to inflammation and*  295 *complement activation.* Finally, we examined plasma glycomes. It has been reported that translocation 296 of glycan-degrading enzymes released by several members of the gut microbiome can alter circulating 297 glycomes (10). Within the plasma glycome, glycans on circulating glycoproteins and antibodies (IgGs 298 and IgAs) play essential roles in regulating several immunological responses, including complement 299 activation (9). For example, galactosylated glycans link Dectin-1 to Fcγ receptor IIB (FcγRIIB) on the

300 surface of myeloid cells to prevent inflammation-mediated by complement activation (9). A loss of 301 galactose decreases the opportunity to activate this anti-inflammatory checkpoint, thus promoting 302 inflammation and complement activation, including during IBD (10). Indeed, IgG glycomic alterations 303 associate with IBD disease progression, and IBD patients have lower IgG galactosylation compared to 304 healthy controls (11).

305 We applied several glycomic technologies to analyze the plasma glycome (total plasma, isolated IgG, 306 and isolated IgA). First, we used capillary electrophoresis to identify the *N*-linked glycans of total 307 plasma glycoproteins and isolated plasma IgG (this identified 24 and 22 glycan structures, respectively; 308 their names and structures are in **Supplementary Tables 3 and 4**). We also used a 45-plex lectin 309 microarray to identify other glycans on total plasma glycoproteins and isolated IgA. The lectin 310 microarray enables sensitive analysis of multiple glycan structures by employing a panel of 45 311 immobilized lectins (glycan-binding proteins) with known glycan-binding specificity (**Supplementary**  312 **Table 5** lists the 45 lectins and their glycan-binding specificities) (29).

313 We first observed significant (FDR<0.05) glycomic differences during severe COVID-19 in levels of 314 IgA glycans, plasma *N*-glycans, plasma total glycans, and IgG glycans (**Figure 6a)**. These changes are 315 exemplified by an apparent loss of the anti-complement activation galactosylated glycans from IgG and 316 total plasma glycoproteins (**Figure 6b-c**, respectively). When we examined the correlations between the 317 plasma glycome and markers of tight junction permeability/microbial translocation 318 inflammation/immune activation (**Supplementary Figure 4**), as expected, we observed significant 319 negative correlations (FDR<0.05) between levels of terminal galactose on IgG or plasma glycoproteins 320 and markers of permeability/ translocation (**Figure 6d**) or markers of inflammation (**Figure 6e**). These 321 data highlight the potential links between the disrupted plasma glycome and systemic inflammation 322 during COVID-19.

323 *Multivariable logistic models, using cross-validation Lasso technique, selected gut-associated*  324 *variables whose combination associates with the risk of hospitalization during COVID-19.* Our data 325 thus far support the hypothesis that gut dysfunction may contribute to COVID-19 severity. We sought to 326 examine whether markers of tight junction permeability and microbial translocation (**Supplementary**  327 **Table 6**) can distinguish between hospitalized COVID-19 patients (moderate and severe groups 328 combined) and non-hospitalized individuals (mild and controls combined). We applied the machine 329 learning algorithm Lasso (least absolute shrinkage and selection operator) regularization to select 330 markers with the highest ability to distinguish between the two groups. The analysis employed samples 331 with complete data sets (n=79; one sample did not have complete data). Lasso selected zonulin, LBP, 332 and sCD14 as the three markers to be included in a multivariable logistic regression model that 333 distinguishes hospitalized from non-hospitalized individuals with area under the ROC curve (AUC) of 334 99.23% (**Figure 7a-b**; 95% confidence interval: 98.1% -100%). This value was higher than the AUC 335 values obtained from logistic models using each variable individually (**Table 2).** Next, we used the 336 multivariable logistic model to estimate a risk score of hospitalization for each individual. We then 337 examined the ability of these risk scores to classify hospitalized from non-hospitalized individuals. As 338 shown in **Figure 7c**, the model correctly classified 97.5% of hospitalized (sensitivity) and 94.9% of non-339 hospitalized (specificity) individuals, with an overall accuracy of 96.2%. Furthermore, we examined the 340 ability of the L-kynurenine/L-tryptophan [Kyn/Trp] ratio, an established marker of gut microbial 341 dysbiosis described above, to distinguish hospitalized from non-hospitalized individuals. Logistic model 342 showed that [Kyn/Trp] ratio alone can distinguish hospitalized from non-hospitalized with an AUC 343 value of 91.9% (**Figure 7d**; 95% confidence interval: >85% -98.7%). These data raise the possibility 344 that some of these markers may be able to predict the risk of disease progression if measured 345 immediately after diagnosis. Markers of intestinal barrier permeability have been used as predictors of

346 multiple organ dysfunction during critical illness (30). Future longitudinal, controlled studies will be 347 needed to assess this possibility.

348 *Zonulin, LBP, and sCD14 plasma levels are higher during severe COVID-19 in an independent*  349 *validation cohort.* Finally, we sought to confirm some of our key findings in an independent cohort of 350 57 individuals tested positive for SARS-CoV-2 and 18 SARS-CoV2 negative controls. The 57 SARS-351 CoV-2 positives were selected to represent three disease states: 20 with mild symptoms (outpatients); 18 352 with moderate symptoms (inpatients hospitalized on regular wards); and 19 with severe symptoms 353 (inpatients hospitalized in an ICU) (**Supplementary Table 2**). We focused on three measurements, 354 zonulin, LBP, and sCD14, as these three measurements together were able to distinguish hospitalized 355 from non-hospitalized individuals in the main cohort (Figure 7a-c). We observed higher levels of 356 zonulin, LBP, and sCD14 during severe COVID-19 in this validation cohort (**Figure 8a-c**). 357 Furthermore, we validated our multivariable logistic model in Figure 7a-c using data from this 358 validation cohort. A combination of zonulin, LBP, and sCD14 was able to distinguishe hospitalized 359 from non-hospitalized individuals in the validation cohort with AUC of 88.6% (95% confidence 360 interval: 80.3% -96.8%; **Table 3**). This analysis further highlights the plausible link between severe 361 COVID-19 and disrupted gut function.

362

#### 363 **DISCUSSION**

364 We used a systems biology approach to provide multiple layers of evidence that severe COVID-19 is 365 associated with markers of disrupted intestinal barrier integrity, microbial translocation, and intestinal 366 dysfunction. These data highlight disruption in gut barrier integrity as a potential force that may 367 contribute to COVID-19 severity. Our data are compatible with previous reports showed that severe 368 COVID-19 is associated with bacterial translocation to the blood and increased levels of microbial-369 associated immune activation markers (31, 32). Our results do not imply that microbial dysbiosis and 370 translocation are the primary triggers of severe COVID-19, as the complex clinical syndrome of severe 371 COVID-19 likely embodies multiple pathophysiological pathways. Also, our *in vivo* analyses do not 372 unequivocally demonstrate a causal relationship between gut dysfunction and COVID-19 severity. 373 However, the robust literature indicating that a disrupted intestinal barrier and microbial dysbiosis and 374 translocation fuel inflammation and disease severity during ARDS (3, 4) supports our hypothesis and is 375 consistent with our findings.

376 SARS-CoV-2 infection can affect the gastrointestinal tract (GI) tract and cause GI symptoms (33). 377 Recently, it has been suggested that the severity of GI symptoms (mainly vomiting and diarrhea) 378 correlates inversely with COVID-19 severity (for unclear reasons) (34). On the other hand, our 379 observations suggest that disruption in gut function and higher microbial translocation correlate 380 positively with COVID-19 severity. These are not necessarily mutually exclusive findings, but rather 381 indicate that the interplay between the gut and SARS-CoV2 infection in modulating disease severity is 382 complex. The potential role of the gut should be further explored, in multiple cohorts and settings, 383 longitudinally during different stages of infection, and using gut biopsies and stool samples. Also, it will 384 be important to examine, in future studies, the location and extent of these potential barrier defects along 385 the length of small and large intestine, using gut biopsies from infected patients and controls.

386 Intestinal disruption during SARS-CoV-2 infection could be caused directly, and/or indirectly. Directly, 387 SARS-CoV-2 can infect gut cells (5); other viral infections of the gut can change gut structure and cause 388 breakdown of the epithelial barrier (6). Indirectly, lung infection or injury leads to systemic 389 inflammation (including a cytokine storm), which then disrupts gut barrier integrity, increasing the

390 permeability to gut microbes and microbial products. Whether the potential disruption of the gut barrier 391 during severe COVID-19 is caused directly by infection and/or indirectly by systemic inflammation and 392 cytokines is not known but warrant further investigations. Also, it will be important to examine the 393 impact of this potential microbial translocation on immune cell functions both in the intestines and 394 systemically.

395 Our data raise several critical questions, including are there long-term implications of the potential 396 disrupted gut barrier and intestinal function in survivors of severe COVID-19? In survivors of SARS-397 CoV-1 infection, long-term health complications (including metabolic dysfunctions) were observed for 398 many years after convalescence (35). HIV+ individuals also can suffer complications of gut microbial 399 translocation for years after viral suppression (36) The current 'long-haulers' (37, 38) after severe 400 COVID-19 may also be on a path towards long term consequences due to persistent, microbial 401 translocation. Understanding the long-term implications of the potential disrupted gut function during 402 severe COVID-19 should be a clinical priority. An accompanying priority should be to consider how to 403 modify clinical practice to prevent or reduce gut disruption. Currently, for example, a large number of 404 patients are receiving antibiotic therapy during their COVID-19 treatment (39). However, massive use 405 of antibiotics can alter gut microbiota and gut function, leading to higher susceptibility to inflammatory 406 disorders (40). Thus, for any clinical practices that alter the gut, their overall impact on disease course 407 should be carefully considered.

408 Our study also reveals several potential therapeutic targets for severe COVID-19, including zonulin. 409 Zonulin is an established modulator of the intestinal tight junctions (15). Microbial dysbiosis and 410 translocation enhance zonulin release, which in turn induces tight junction permeability, leading to more 411 microbial translocation. This microbial translocation triggers inflammation, which promotes further gut 412 leakiness (17, 18). Increased intestinal permeability and serum zonulin levels have been observed during 413 many inflammatory diseases, including Crohn's disease (41). Preventing zonulin-mediated increase in 414 intestinal permeability by a zonulin receptor antagonist AT1001 (larazotide acetate) decreased the 415 severity and incidence of several inflammation-associated diseases in pre-clinical and clinical studies 416 (42-44). The high levels of serum zonulin we observed during severe COVID-19, which were associated 417 with inflammation and mortality, raise the question of whether modulators of tight junction permeability 418 (such as with AT-1001) can lessen COVID-19 severity.

419 Our data show a disruption in several multi-faceted metabolic pathways, some of which are linked to gut 420 functions. Plasma citrulline levels were lower in both moderate and severe COVID-19 patients 421 compared to the mild and control groups, and the citrulline metabolism and biosynthesis pathways were 422 among the top metabolic pathways disrupted in severe COVID-19. Citrulline is an intermediate in 423 arginine metabolism (45), and is an established marker of gut and enterocyte function (22, 46). 424 Disrupted citrulline metabolism, as we observed during severe COVID-19, has been associated with 425 microbial dysbiosis and dysregulated intestinal function (47). However, ACE2 blocking is an alternative 426 explanation of the low levels of citrulline. ACE2 is required for the function of amino acid transporters 427 (48). Thus, the binding of SARS-CoV-2 to ACE2 may reduce the functions of amino acid transporters, 428 leading to the reduction of citrulline and other amino acids such as tryptophan. Additionally, plasma 429 citrulline levels might be an indication of defects in liver and/or kidney functions (49). We also observed 430 high levels of succinic acid and kynurenic acid. Both metabolites have been associated with intestinal 431 microbial dysbiosis (23, 50). However, succinic acid has also been associated with mucosal hypoxia 432 (50). To what extend the disruption of intestinal barrier integrity and microbial dysbiosis contribute to 433 these disrupted metabolic pathways should the subject of future studies. These studies will help us to 434 better understand the interaction between the gut, intestinal microbiota, and amino acid metabolism

435 during COVID-19. This understanding might be critical to inform pharmaceutical and diet approaches to 436 improve COVID-19 outcomes.

437 A significant strength of our multi-omics approach is its ability to uncover connections between severe 438 COVID-19 and biomolecules of different classes. The carbohydrate structures (glycans) attached to 439 circulating proteins, including antibodies, and their receptors (lectins) are increasingly being appreciated 440 for their essential roles in a variety of immune functions. Among the glycobiological molecules 441 regulated by severe COVID-19 are galectins (increasing) and galactosylated glycans on circulating 442 glycoproteins (decreasing). Both may point to potential glycomic contributions to the severity of 443 COVID-19. First, galectins (secreted, GalNAc-binding proteins) have emerged as significant modulators 444 of cytokine expression by immune cells during several diseases, including viral infections (51). 445 Importantly, small molecule inhibitors for galectins, especially for Gal-3, can reduce inflammation and 446 cytokine release (52). Therefore, galectins represent potential therapeutic targets to reduce cytokine 447 storm during COVID-19 (53).

448 Caveats of our study include the sample size and sampling of blood. As noted above, correcting for 449 potential confounders (such as ethnicity) will require larger cohorts from varying geographic and 450 demographic settings. Additional independent test sets and samples from non-COVID1-9 hospitalized 451 and ICU-admitted patients will also be needed. Longitudinal analyses will be required to examine the 452 long-term implications of our findings and their potential value as prognostic biomarkers. Analysis of 453 gut biopsies, stool, and bronchial lavage will be needed to determine the precise contributions of the gut-454 lung axis in COVID-19. Analyzing the impact of the potential microbial translocation during severe 455 COVID-19 on particular immune cell (such as Th17) in the intestines and systemically, will be also 456 needed. Furthermore, environmental differences in diet and social environment may impact intestinal 457 inflammation, therefore, future studies to understand the potential impact of socioeconomic status on the 458 potential link between microbial translocation and severe COVID-19 will be needed. Finally, 459 mechanistic studies *in vitro* and in animal models of SARS-CoV2 infection will be needed to examine 460 the direct versus the indirect impact of the infection on intestinal barrier integrity and function.

461 In summary, while this study was exploratory in nature, our data suggest: (1) severe COVID-19 is 462 associated with markers of a) disrupted intestinal barrier integrity; b) higher microbial translocation; and 463 c) gut dysfunction; (2) severe COVID-19 is associated with a dramatic shift in levels of several 464 biologically active molecules, which likely contribute to disease severity by inducing inflammation. Our 465 study is beginning to shed light on the potentially critical role of intestinal barrier integrity in the 466 pathophysiology of severe COVID-19. By understanding these underappreciated underpinnings of 467 COVID-19, this work may serve to identify biomarkers for risk stratification and build a foundation for 468 developing strategies to prevent or reduce the severity of COVID-19.

#### 469 **FIGURE LEGENDS**

470 **Figure 1. Severe COVID-19 is associated with an increase in markers of tight junction**  471 **permeability and microbial translocation. (a)** An overview of the main cohort study design; 472 moderate and severe patients were hospitalized; severe indicates patients in the intensive care 473 unit. **(b)** Levels of plasma zonulin, are higher during moderate and severe COVID-19 compared 474 to mild COVID-19 or controls. Kruskal–Wallis test was used for statistical analysis. False 475 discovery rate (FDR) was calculated using the Benjamini-Hochberg method. Symbols in black 476 indicate deceased. **(c)** Zonulin levels are higher in hospitalized COVID patients (n=40) who 477 eventually died from COVID-19 (n=8) compared to survivors (n=32). Nominal *P*-value was 478 calculated using the Mann–Whitney U test. **(d-g)** Levels of LBP **(d)**, β-Glucan **(e)**, sCD14 **(f)**, and MPO (g), are higher during severe COVID-19 compared to mild COVID-19 or controls. 480 Kruskal–Wallis test was used for statistical analysis. FDR was calculated using Benjamini-481 Hochberg method. Black dots indicate deceased.

482 **Figure 2. Markers of tight junction permeability and microbial translocation are associated**  483 **with markers of systemic inflammation. (a left)** Heat-map depicting plasma levels of 23 484 inflammation and immune activation/dysfunction markers whose levels are statistically 485 (FDR<0.05) different between the four disease states. Statistical significance was determined 486 using the Kruskal–Wallis test. FDR was calculated using Benjamini-Hochberg method. SC *rho* = 487 coefficient of correlation with COVID-19 severity. Heat colors show standardized Z-scores 488 across samples; red indicates upregulation, and blue indicates downregulation. **(a right)** 489 Coefficients of correlation between zonulin, LBP, or β-Glucan and each of the 23 inflammation and immune activation/dysfunction markers. All red-colored correlations had statistical and immune activation/dysfunction markers. All red-colored correlations had statistical 491 significance of FDR<0.05, whereas the grey-colored correlation was non-significant. 492 Correlations were evaluated using Spearman's rank correlation tests, and FDR was calculated 493 using the Benjamini-Hochberg method. **(b-d)** Levels of representative variables, galectin-3 (Gal-494 3) **(b)** and galectin-9 (Gal-9) **(c),** were higher during severe COVID-19 compared to mild 495 COVID-19 or controls, with levels of Gal-9 higher among deceased hospitalized patients 496 compared to survivors **(d)**. **(e-g)** Levels of C3a **(e)** and GDF-15 **(f)** were higher during severe 497 COVID-19 compared to mild COVID-19 or controls, with levels of GDF-15 higher among 498 deceased hospitalized patients compared to survivors **(g)**. Kruskal–Wallis and Mann-Whitney 499 tests were used for statistical analysis. FDR was calculated using Benjamini-Hochberg method. <sup>500</sup>**(h-i)** Examples of correlations in (a) between LBP and IL-6 **(h)** or β-Glucan and IL-6 **(i)**. Spearman's rank correlation tests were used for statistical analysis. Black dots indicate deceased.

502 **Figure 3. Severe COVID-19 is associated with metabolic dysregulation. (a)** Principal 503 component analysis (PCA) of the 278 metabolites identified in the plasma of the study cohort. 504 Each symbol represents a study participant. **(b)** Ingenuity Pathway Analysis (IPA) of the plasma 505 metabolites modulated between the disease states with FDR<0.05. The graph shows the top 10 506 dysregulated metabolic pathways with FDR<0.05. Percentages beside each pathway represent 507 the ratio of dysregulated metabolites among the total number of metabolites assigned to this 508 particular pathway in IPA. **(c)** Volcano plots depicting plasma metabolites dysregulated in the 509 moderate group compared to the mild group (left) or the severe group compared to the mild 510 group (right). NS= non-significant. The gut-associated metabolites (from Table 1) are indicated 511 by the larger symbols, and a selected set is identified by name. **(d-f)** As representative examples, 512 levels of citrulline are lower **(d)**, levels of succinic acid are higher **(e)**, and the ratio between

513 kynurenine/tryptophan [Kyn/Trp] is higher **(f)** during severe COVID-19 compared to mild 514 COVID-19 or controls. Kruskal–Wallis test was used for statistical analysis. FDR was calculated 515 using Benjamini-Hochberg method. **(g-h)** For key metabolites in the tryptophan catabolism 516 pathway, levels of tryptophan are lower **(g)**, and levels of kynurenic acid are higher **(h)** in 517 deceased COVID-19 hospitalized patients compared to survivors. Nominal *P*-value was 518 calculated using the Mann–Whitney U test. Black dots indicate deceased.

519 **Figure 4. Metabolic markers of intestinal dysfunction are linked to microbial translocation**  520 **and systemic inflammation.** Correlation heat-maps depicting the correlations between COVID-521 19-modulated, gut-associated metabolites, and **(a)** markers of tight junction permeability and 522 microbial translocation or (**b**) markers of inflammation and immune dysfunction. SC *rho* = 523 coefficient of correlation with COVID-19 severity. Red-colored correlations = significant 524 positive correlations with FDR<0.05, blue-colored correlations = significant negative 525 correlations with FDR<0.05, gray-colored correlations = non-significant (FDR>0.05). **(c-e)**  526 Examples of the correlations between citrulline and IL-6 **(c)**, succinic acid and IL-6 **(d),** or 527 [Kyn/Trp] ratio and IL-6 **(e)**. Spearman's rank correlation tests were used for statistical analysis. 528 FDR was calculated using Benjamini-Hochberg method.

529 **Figure 5. Severe COVID-19 is associated with disrupted lipid metabolism. (a)** Principal 530 component analysis (PCA) of 2015 lipids identified in the plasma of the study cohort. **(b)** The 531 2015 identified lipids were assigned to 24 classes (Supplementary Table 5). Heat-map depicts the 532 16 lipid classes dysregulated by severe COVID-19 (FDR<0.05). Statistical significance was 533 determined using the Kruskal–Wallis test. FDR was calculated using Benjamini-Hochberg 534 method. SC *rho* = coefficient of correlation with COVID-19 severity. Heat colors show 535 standardized Z-scores across samples; red indicates upregulation, and blue indicates 536 downregulation. **(c)** Lipid pathway analysis of the plasma lipids modulated between the disease 537 states with FDR<0.05 was performed using LIPEA (Lipid Pathway Enrichment Analysis; 538 https://lipea.biotec.tu-dresden.de/home). The graph includes all dysregulated pathways with 539 FDR<0.05. Percentages beside each pathway represent the ratio of dysregulated lipids among the 540 total number of lipids assigned to this particular pathway by LIPEA.

541 **Figure 6. Severe COVID-19 is associated with plasma glycomic dysregulations. (a)** Heat-542 map depicting glycans dysregulated by severe COVID-19 (FDR<0.05). Names of the glycan-543 binding lectins are provided in parentheses. Statistical significance was determined using the 544 Kruskal–Wallis test. FDR was calculated using Benjamini-Hochberg method. SC *rho* = 545 coefficient of correlation with COVID-19 severity. Heat colors show standardized Z-scores 546 across samples; red indicates upregulation, and blue indicates downregulation. **(b-c)** Levels of 547 terminal digalactosylated *N*-glycans in IgG **(b)** or total plasma glycoproteins **(c)** are lower during 548 severe COVID-19 compared to mild COVID-19 or controls. Kruskal–Wallis test. FDR was 549 calculated using Benjamini-Hochberg method. **(e-d)** Correlation heat-maps depicting the 550 correlations between galactosylated *N*-glycans (rows) and markers of tight junction permeability 551 and microbial translocation **(d)** or markers of inflammation and immune dysfunction (**e**). SC *rho* 552 = coefficient of correlation with COVID-19 severity. Red-colored correlations = significant 553 positive correlations with FDR<0.05, blue-colored correlations = significant negative 554 correlations with FDR<0.05, and gray-colored correlations = non-significant. Spearman's rank 555 correlation tests were used for statistical analysis. FDR was calculated using Benjamini-556 Hochberg method. Black dots indicate deceased.

557 **Figure 7. Logistic models using markers of tight-junction permeability and microbial**  558 **translocation distinguish hospitalized from non-hospitalized individuals**. **(a-b)** The machine 559 learning algorithm, Lasso (least absolute shrinkage and selection operator) regularization, 560 selected three markers (zonulin, LBP, and sCD14) that, when combined, can distinguish 561 hospitalized from non-hospitalized individuals. (a) The receiver operator characteristic (ROC) 562 curve from the multivariable logistic regression model with the three variables combined. (b) 563 feature importance plot. (**c**) Coefficients from the multivariable logistic model were used to 564 estimate a hospitalization risk score for each individual and then tested for the ability of these 565 scores to accurately classify hospitalized (n=40) from non-hospitalized (n=39; one sample did 566 not have a complete dataset) individuals at an optimal cut-point. Squares represent individuals 567 the model failed to identify correctly. **(d)** Logistic regression model using the L-kynurenine/L-568 tryptophan [Kyn/Trp] ratio is able to distinguish hospitalized from non-hospitalized individuals. 569 ROC curve showing the area under the curve (AUC) is 91.3%.

570 **Figure 8. Validation of key measurements in an independent cohort**. Levels of plasma **(a)**  571 zonulin, **(b)** LBP, and **(c)** sCD14 are higher during moderate and severe COVID-19 compared to 572 mild COVID-19 or controls in an independent validation cohort. Kruskal–Wallis test was used 573 for statistical analysis.

- 574
- 575 **TABLES**

576 **Table 1.** Levels of the 35 (out of 50) gut- and gut microbiota-associated plasma metabolites that 577 are disrupted during COVID-19. Red indicates upregulation, blue indicates downregulation; 578 color intensity indicates larger difference. Green indicates FDR<0.05; color intensity indicates 579 lower FDR.

580 **Table 2.** Results of logistic regression models of tight junction permeability and microbial 581 translocation markers for ability to distinguish hospitalized from non-hospitalized individuals.

582 **Table 3.** AUC values of the logistic regression model built with data from the main cohort and 583 validated with data from the validation cohort.

584

585

#### 586 **SUPPLEMENTARY MATERIALS**

587 **Supplementary Figure 1: Age was not significantly different between the groups in the main**  588 **cohort.** Kruskal–Wallis test was used for statistical analysis

589 **Supplementary Figure 2: Top 50 metabolites dysregulated by COVID-19.** Heat-maps depicting the 590 top 25 metabolites induced and the top 25 metabolites reduced by COVID-19 (FDR<0.05). Statistical 591 significance was determined using the Kruskal–Wallis test. FDR was calculated using Benjamini-592 Hochberg method. SC *rho* = coefficient of correlation with COVID-19 severity. Heat colors show 593 standardized Z-scores across samples; red indicates upregulation, and blue indicates downregulation.

594 **Supplementary Figure 3: Levels of key markers are not different between groups with different**  595 **diabetes or blood pressure status. (a)** No = non-diabetic; Pre = Pre-diabetic; and Yes = diabetic. 596 Statistical significance was determined using the Kruskal–Wallis test (ns = non-significant; *P*>0.05). **(b)**  597 No = not suffering from high blood pressure and Yes = suffering from high blood pressure. Statistical 598 significance was determined using the Mann–Whitney U test (ns = non-significant; *P*>0.05).

599 **Supplementary Figure 4: The COVID-19-associated plasma glycomic signatures are associated**  600 **with microbial translocation and systemic inflammation.** Correlation heat-maps depicting the 601 correlations between COVID-19 modulated plasma glycans and **(a)** markers of tight junction 602 permeability and microbial translocation or (**b**) markers of inflammation and immune dysfunction. SC 603 *rho* = coefficient of correlation with COVID-19 severity. Red-colored correlations = significant positive 604 correlations with FDR<0.05, blue-colored correlations = significant negative correlations with  $605$  FDR<0.05, and gray-colored correlations = non-significant correlations.

- 606 **Supplementary Table 1.** Demographic and clinical characteristics of the study cohort.
- 607 **Supplementary Table 2.** Demographic characteristics of the validation cohort.

608 **Supplementary Table 3.** The structures and names of *N*-glycans identified in plasma by capillary 609 electrophoresis. These glycan structures can be grouped into 15 groups: bisecting GlcNAc (B group), 610 sialic acid (non-sialylated (S0), mono-sialylated (S1), di-sialylated (S2), tri-sialylated and (S3), tetra-611 sialylated (S4), and total sialylated (ST)), galactose (agalactosylated (G0), mono-galactosylated (G1), di-612 galactosylated (G2), and total galactosylated (GT)), core fucose (FC group), branched fucose (FB 613 group), high branched (HB group), and low branch (LB group).

614 **Supplementary Table 4.** The structures and names of *N*-glycans identified in IgG by capillary 615 electrophoresis. These glycan structures were grouped into 9 groups, depending on the presence or 616 absence of four key monosaccharides: bisecting GlcNAc (B group), sialic acid (mon-sialylated (S1), di-617 sialylated (S2), and total sialylated (ST)), terminal galactose (agalactosylated (G0), mono-618 galactosylated (G1), di-galactosylated (G2), and total galactose (GT)), and fucose (F group).

- 619 **Supplementary Table 5.** Lectins used in the 45-plex lectin microarray and their glycan-binding 620 specificity.
- 621 **Supplementary Table 6:** A list of plasma markers measured in this study.
- 622 **Supplementary Table 7:** Top 50 metabolic pathways disrupted by severe COVID-19.

623 **Supplementary Table 8:** List of the gut-associated and gut microbiota-associated metabolites detected 624 in our study using untargeted LC-MS/MS (50 of the 278 metabolites identified in plasma).

625 **Supplementary Table 9.** The two thousand fifteen lipids identified in this study were assigned to 24 626 lipid classes.

#### 627 **ACKNOWLEDGMENTS**

628 This study is supported by a supplement to the NIH R01 DK123733 (R01 DK123733-01S1) for M.A-M,

629 A.L, and A.Ke and R24 AA026801- 02S1 for A.Ke. M.A-M is also supported by The Foundation for

630 AIDS Research (amfAR) impact grant # 109840-65-RGR, NIH grants (R01 AG062383, R01NS117458,

631 R21 AI143385, R21 AI129636, and R21 NS106970), and the Penn Center for AIDS Research (P30 AI

632 045008). The Wistar Proteomics and Metabolomics Shared Resource is supported in part by NIH

633 Cancer Center Support Grant CA010815. The Thermo Q-Exactive HF-X mass spectrometer was

- 634 purchased with NIH grant S10 OD023586. We would like to thank Rachel E. Locke, Ph.D., for
- 635 providing comments.
- 636

#### 637 **AUTHOR CONTRIBUTIONS**

638 M.A-M, A.L, and A.Ke conceived and designed the study. L.B.G. carried out the majority of 639 experiments. H.D., X.Y, H.W, Q.L, and A.Ko performed all bioinformatics and biostatistical analyses. 640 M.D. ran the lectin array experiments. C.S.P reviewed and selected gut-associated metabolites. N.F.Z, 641 R.A.B, M.W.S, CBF, A.Ke, and A.L selected study participants and interpreted data. A.R.G, N.G, and 642 H.T performed metabolic and lipidomic analyses. L.B.G. and M.A-M wrote the manuscript, and all 643 authors edited it.

644

#### 645 **COMPETING INTERESTS STATEMENT**

646 Authors have have no competing interests.

#### 647 **REFERENCES**

- 648 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. 2020. Clinical Characteristics of 649 Coronavirus Disease 2019 in China. N Engl J Med 382:1708-1720.
- 650 2. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. 2020. 651 Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181:1036- 652 1045 e9.
- 653 3. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. 2018. The role of the lung 654 microbiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol 20:e12966.
- 655 4. Dickson RP, Singer BH, Newstead MW, Falkowski NR, Erb-Downward JR, Standiford TJ, et al. 656 2016. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory 657 distress syndrome. Nat Microbiol 1:16113.
- 658 5. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. 2020. SARS-659 CoV-2 productively infects human gut enterocytes. Science doi:10.1126/science.abc1669.
- 660 6. Turner JR. 2009. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 661 9:799-809.
- 662 7. Mayneris-Perxachs J, Fernandez-Real JM. 2020. Exploration of the microbiota and metabolites 663 within body fluids could pinpoint novel disease mechanisms. FEBS J 287:856-865.
- 664 8. Davaatseren M, Hwang JT, Park JH, Kim MS, Wang S, Sung MJ. 2013. Poly-gamma-glutamic 665 acid attenuates angiogenesis and inflammation in experimental colitis. Mediators Inflamm 666 2013:982383.
- 667 9. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. 2012. Anti-668 inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB 669 and dectin-1. Nat Med 18:1401-6.
- 670 10. Cao Y, Rocha ER, Smith CJ. 2014. Efficient utilization of complex N-linked glycans is a 671 selective advantage for Bacteroides fragilis in extraintestinal infections. Proc Natl Acad Sci U S 672 A 111:12901-6.
- 673 11. Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D, et al. 2018. 674 Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel 675 Diseases. Gastroenterology 154:1320-1333 e10.
- 676 12. Monaghan TM, Pucic-Bakovic M, Vuckovic F, Lee C, Kao D, Human Glycome P. 2019. 677 Decreased Complexity of Serum N-glycan Structures Associates with Successful Fecal 678 Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology 679 157:1676-1678 e3.
- 680 13. Li J, Agarwal E, Bertolini I, Seo JH, Caino MC, Ghosh JC, et al. 2020. The mitophagy effector 681 FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Sci 682 Signal 13.
- 683 14. Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, et al. 2020. 684 Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell 685 Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. Cancer Discov 10:1282- 686 1295.
- 687 15. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, et al. 688 2009. Identification of human zonulin, a physiological modulator of tight junctions, as 689 prehaptoglobin-2. Proc Natl Acad Sci U S A 106:16799-804.
- 690 16. Fasano A. 2011. Zonulin and its regulation of intestinal barrier function: the biological door to 691 inflammation, autoimmunity, and cancer. Physiol Rev 91:151-75.
- 692 17. El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, et al. 2002. Host-dependent 693 zonulin secretion causes the impairment of the small intestine barrier function after bacterial 694 exposure. Gastroenterology 123:1607-15.



- 742 34. Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, et al. 2020. 743 Gastrointestinal involvement attenuates COVID-19 severity and mortality. medRxiv 744 doi:10.1101/2020.09.07.20187666:2020.09.07.20187666.
- 745 35. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. 2017. Altered Lipid Metabolism in Recovered 746 SARS Patients Twelve Years after Infection. Sci Rep 7:9110.
- 747 36. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, et al. 2015. Intestinal 748 microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect 749 Dis 211:19-27.
- 750 37. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. 2020. Persistent Symptoms in 751 Patients After Acute COVID-19. JAMA 324:603-605.
- 752 38. Anonymous. 2020. Meeting the challenge of long COVID. Nat Med 26:1803.
- 753 39. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. 2020. Epidemiological and clinical 754 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive 755 study. Lancet 395:507-513.
- 756 40. Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. 2016. Antibiotics promote 757 inflammation through the translocation of native commensal colonic bacteria. Gut 65:1100-9.
- 758 41. Sturgeon C, Fasano A. 2016. Zonulin, a regulator of epithelial and endothelial barrier functions, 759 and its involvement in chronic inflammatory diseases. Tissue Barriers 4:e1251384.
- 760 42. Tajik N, Frech M, Schulz O, Schalter F, Lucas S, Azizov V, et al. 2020. Targeting zonulin and 761 intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun 11:1995.
- 762 43. Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R, et al. 2005. Role of the intestinal tight 763 junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc 764 Natl Acad Sci U S A 102:2916-21.
- 765 44. Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, et al. 2015. Larazotide 766 acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized 767 controlled trial. Gastroenterology 148:1311-9 e6.
- 768 45. Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Benazeth S, et al. 2005. Almost all about 769 citrulline in mammals. Amino Acids 29:177-205.
- 770 46. Peters JH, Beishuizen A, Keur MB, Dobrowolski L, Wierdsma NJ, van Bodegraven AA. 2011. 771 Assessment of small bowel function in critical illness: potential role of citrulline metabolism. J 772 Intensive Care Med 26:105-10.
- 773 47. Kao CC, Cope JL, Hsu JW, Dwarkanath P, Karnes JM, Luna RA, et al. 2015. The Microbiome, 774 Intestinal Function, and Arginine Metabolism of Healthy Indian Women Are Different from 775 Those of American and Jamaican Women. J Nutr 146:706-713.
- 776 48. Camargo SMR, Vuille-Dit-Bille RN, Meier CF, Verrey F. 2020. ACE2 and gut amino acid 777 transport. Clin Sci (Lond) 134:2823-2833.
- 778 49. Lau T, Owen W, Yu YM, Noviski N, Lyons J, Zurakowski D, et al. 2000. Arginine, citrulline, 779 and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest 105:1217-25.
- 780 50. Connors J, Dawe N, Van Limbergen J. 2018. The Role of Succinate in the Regulation of 781 Intestinal Inflammation. Nutrients 11.
- 782 51. Wang WH, Lin CY, Chang MR, Urbina AN, Assavalapsakul W, Thitithanyanont A, et al. 2019. 783 The role of galectins in virus infection - A systemic literature review. J Microbiol Immunol 784 Infect doi:10.1016/j.jmii.2019.09.005.
- 785 52. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, et al. 2012. 786 Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir 787 Crit Care Med 185:537-46.
- 788 53. Caniglia JL, Guda MR, Asuthkar S, Tsung AJ, Velpula KK. 2020. A potential role for Galectin-3 789 inhibitors in the treatment of COVID-19. PeerJ 8:e9392.

- 790 54. Gonthier MP, Cheynier V, Donovan JL, Manach C, Morand C, Mila I, et al. 2003. Microbial 791 aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols 792 excreted in urine of rats fed red wine polyphenols. J Nutr 133:461-7.
- 793 55. Pellock SJ, Redinbo MR. 2017. Glucuronides in the gut: Sugar-driven symbioses between microbe and host. J Biol Chem 292:8569-8576.
- 795 56. Monagas M, Urpi-Sarda M, Sanchez-Patan F, Llorach R, Garrido I, Gomez-Cordoves C, et al. 796 2010. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and 797 the bioactivity of their metabolites. Food Funct 1:233-53.
- 798 57. Zhitao H, Ailin S, Qingshuang W, Changyuan H, Liying S, Xianming S, et al. 2020. Research 799 Square doi:10.21203/rs.3.rs-70833/v1.
- 800 58. Coman V, Vodnar DC. 2020. Hydroxycinnamic acids and human health: recent advances. J Sci 801 Food Agric 100:483-499.
- 802 59. Skrzypecki J, Nieweglowska K, Samborowska E. 2020. Valeric Acid, a Gut Microbiota Product, 803 Penetrates to the Eye and Lowers Intraocular Pressure in Rats. Nutrients 12.
- 804 60. Marhuenda-Munoz M, Laveriano-Santos EP, Tresserra-Rimbau A, Lamuela-Raventos RM, 805 Martinez-Huelamo M, Vallverdu-Queralt A. 2019. Microbial Phenolic Metabolites: Which 806 Molecules Actually Have an Effect on Human Health? Nutrients 11.
- 807 61. Selkrig J, Wong P, Zhang X, Pettersson S. 2014. Metabolic tinkering by the gut microbiome: 808 Implications for brain development and function. Gut Microbes 5:369-80.
- 809 62. Farowski F, Els G, Tsakmaklis A, Higgins PG, Kahlert CR, Stein-Thoeringer CK, et al. 2019. 810 Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance 811 of Clostridiales. Gut Microbes 10:133-141.
- 812 63. Huang YY, Martinez-Del Campo A, Balskus EP. 2018. Anaerobic 4-hydroxyproline utilization: 813 Discovery of a new glycyl radical enzyme in the human gut microbiome uncovers a widespread 814 microbial metabolic activity. Gut Microbes 9:437-451.
- 815 64. Rea K, Dinan TG, Cryan JF. 2016. The microbiome: A key regulator of stress and 816 neuroinflammation. Neurobiol Stress 4:23-33.
- 817 65. Pan L, Han P, Ma S, Peng R, Wang C, Kong W, et al. 2020. Abnormal metabolism of gut 818 microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia. 819 Acta Pharm Sin B 10:249-261.
- 820 66. Molinero N, Ruiz L, Sanchez B, Margolles A, Delgado S. 2019. Intestinal Bacteria Interplay 821 With Bile and Cholesterol Metabolism: Implications on Host Physiology. Front Physiol 10:185.
- 822 67. Arias N, Arboleya S, Allison J, Kaliszewska A, Higarza SG, Gueimonde M, et al. 2020. The 823 Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and 824 Its Modulation of Human Diseases. Nutrients 12.
- 825 68. Maekawa M, Maekawa M, Ushida K, Hoshi S, Kashima N, Ajisaka K, et al. 2005. Butyrate and 826 propionate production from D-mannitol in the large intestine of pig and rat. Microbial Ecology in 827 Health and Disease 17:169-176.
- 828 69. Utzschneider KM, Kratz M, Damman CJ, Hullar M. 2016. Mechanisms Linking the Gut 829 Microbiome and Glucose Metabolism. J Clin Endocrinol Metab 101:1445-54.
- 830 70. Mathewson ND, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, et al. 2016. Gut 831 microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-832 versus-host disease. Nat Immunol 17:505-513.
- 833 71. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. 2014. Bile acids and the gut microbiome. Curr 834 Opin Gastroenterol 30:332-8.
- 835 72. Di Rienzi SC, Britton RA. 2020. Adaptation of the Gut Microbiota to Modern Dietary Sugars 836 and Sweeteners. Adv Nutr 11:616-629.
- 837 73. Craft IL, Geddes D, Hyde CW, Wise IJ, Matthews DM. 1968. Absorption and malabsorption of 838 glycine and glycine peptides in man. Gut 9:425-37.

- 839 74. Yasumoto K, Sugiyama K. 1980. Perturbation by Bestatin of Glycyl-l-leucine Absorption in 840 Isolated Epithelial Cells from Rat Intestine. Agricultural and Biological Chemistry 44:1339- 841 1344.
- 842 75. Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. 2018. Impact of the Gut Microbiota on 843 Intestinal Immunity Mediated by Tryptophan Metabolism. Front Cell Infect Microbiol 8:13.
- 844 76. Krautkramer KA, Fan J, Backhed F. 2020. Gut microbial metabolites as multi-kingdom 845 intermediates. Nat Rev Microbiol doi:10.1038/s41579-020-0438-4.
- 846 77. Jain A, Li XH, Chen WN. 2019. An untargeted fecal and urine metabolomics analysis of the 847 interplay between the gut microbiome, diet and human metabolism in Indian and Chinese adults. 848 Sci Rep 9:9191.
- 849 78. Zhang L, Ouyang Y, Li H, Shen L, Ni Y, Fang Q, et al. 2019. Metabolic phenotypes and the gut 850 microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized 851 crossover trial. Sci Rep 9:4736.
- 852 79. Oliphant K, Allen-Vercoe E. 2019. Macronutrient metabolism by the human gut microbiome: 853 major fermentation by-products and their impact on host health. Microbiome 7:91.
- 854 80. Kong J-Q. 2015. Phenylalanine ammonia-lyase, a key component used for phenylpropanoids 855 production by metabolic engineering. RSC Advances 5:62587-62603.
- 856 81. Heianza Y, Ma W, DiDonato JA, Sun Q, Rimm EB, Hu FB, et al. 2020. Long-Term Changes in 857 Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk. J Am Coll 858 Cardiol 75:763-772.

859



















 $\mathbf b$ 



 $\mathbf d$ 

Logistic model using [Kyn/Trp] ratio



# **Validation cohort**

